Drug Development and Regulation · eu
Evaluated in Under 150 Days: Pancreatic Cancer Drug daraxonrasib Becomes First to Receive EMA Recommendation Through Phased Review
The European Medicines Agency has issued its first recommendation for marketing authorisation through phased review, bringing patients with advanced pancreatic cancer and limited treatment options closer to an oral therapy. However, further steps remain between the expert committee’s endorsement, formal authorisation and reimbursement in individual countries.
For patients with metastatic pancreatic cancer whose disease has progressed after prior treatment, waiting for a new drug is also a race against the disease. On October 15, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of the oral drug Rasonque (daraxonrasib), issuing its first recommendation for marketing authorisation through “phased review.” This development involves changes in both treatment options and the review process, but the European Commission has yet to issue a formal approval decision.
Phased review moves part of the assessment to before submission of the complete application. Regulators progressively examine evidence on drug quality, nonclinical studies and clinical studies as the company submits data, addressing issues early through ongoing scientific discussions. The Spanish Agency of Medicines and Medical Devices (AEMPS) stated that Rasonque is the first medicine to receive a recommendation for marketing authorisation under this procedure.
According to EMA, this assessment took fewer than 150 days. The standard procedure requires up to 210 active review days, plus the time the company takes to respond to questions, typically bringing the total to about a year. The key to shortening the wait is starting earlier and reviewing data in stages. EMA emphasised that the standards for reviewing quality, safety and efficacy remain unchanged. Future use of the same pathway will be determined by each medicine’s medical need and public health value.
The core evidence supporting the recommendation came from the phase 3 RASolute 302 trial, which enrolled 500 participants and compared daraxonrasib with chemotherapy. There are two analyses of the survival data, and they must be distinguished: according to Revolution Medicines’ announcement, the prespecified primary analysis showed median overall survival of 13.2 months versus 6.7 months; a subsequent additional analysis showed 12.4 months versus 6.7 months, with a hazard ratio for death of 0.49. EMA’s news release used the latter set of overall survival data. The two sets are not results from different trials.
Daraxonrasib works by first forming a complex with cyclophilin A inside cells, then blocking interactions between RAS and downstream signalling molecules to inhibit signals that promote cancer cell growth. The recommended indication is use as a single agent in adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy; the recommendation does not restrict use to a specific RAS mutation. However, 92% of patients in the trial were confirmed to have RAS G12 mutations, and this composition must be considered when interpreting efficacy in other molecular subgroups.
Beyond efficacy, treatment burden also needs to be considered. Common adverse reactions listed by EMA include diarrhoea, rash, stomatitis, nausea and vomiting. Median survival reflects the overall results of the trial population and cannot predict how long an individual patient will survive. Full prescribing recommendations and risk management information will be further detailed in the summary of product characteristics published after formal approval.
Next, the CHMP opinion will be submitted to the European Commission to decide whether to grant EU-wide marketing authorisation. Even if approval is granted, each member state must separately address pricing and reimbursement. This first case shows that reviewing data early can shorten regulatory waiting times. When patients can actually access the medicine will still depend on approval and subsequent arrangements within national healthcare systems.